This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
by Zacks Equity Research
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
by Zacks Equity Research
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
by Zacks Equity Research
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
by Zacks Equity Research
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -21.74% and 86.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
by Zacks Equity Research
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
by Zacks Equity Research
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -11.94% and 22.55%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
by Zacks Equity Research
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
by Zacks Equity Research
The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
by Zacks Equity Research
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.